Market: NASD |
Currency: USD
Address: 345 Park Avenue South
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
📈 Protara Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$24.20
-
Upside/Downside from Analyst Target:
649.23%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
-0.38
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2020 |
- |
$0.025000 |
- |
2020-01-10 |
- |
Stock split |
|
Total Amount for 2020: $0.025000 |
📅 Earnings & EPS History for Protara Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-12 (estimated upcoming) | - |
| 2025-08-11 | -0.35 |
| 2025-05-08 | -0.29 |
| 2025-03-05 | -0.43 |
| 2024-11-12 | -0.5 |
| 2024-08-06 | -0.45 |
| 2024-05-02 | -0.97 |
| 2024-03-13 | -0.9 |
| 2023-11-03 | -0.87 |
| 2023-08-03 | -1 |
| 2023-05-04 | -0.8 |
| 2023-03-08 | -0.84 |
| 2022-11-03 | -0.68 |
| 2022-08-09 | -0.8 |
| 2022-05-05 | -0.96 |
| 2022-03-09 | -0.91 |
| 2021-11-04 | -0.96 |
| 2021-08-05 | -1.14 |
| 2021-05-06 | -1.2 |
| 2021-03-11 | -0.44 |
| 2021-03-10 | -0.6 |
| 2020-11-12 | -1.26 |
| 2020-07-31 | -1.22 |
| 2020-05-13 | -1.81 |
📰 Related News & Research
No related articles found for "protara therapeutics".
